Recombinant Human a2M Protein，His

α2-macroglobulin (A2M) is a large plasma glycoprotein that plays a crucial role in regulating protease activity and modulating inflammatory responses. Originally identified for its ability to inhibit a wide range of proteases by undergoing a unique conformational change upon enzyme binding, A2M also acts as a carrier for various growth factors and cytokines, influencing cellular processes and tissue regeneration. Research into A2M has gained momentum due to its potential implications in several pathophysiological conditions, including neurodegenerative diseases, cancer, and chronic inflammation. A2M’s involvement in neuronal protection and its ability to sequester harmful proteases has sparked interest in its therapeutic potential for conditions such as Alzheimer’s disease and multiple sclerosis. Additionally, studies have highlighted the role of A2M in modulating the immune response, making it a candidate for therapeutic interventions in autoimmune disorders. The recent advancements in recombinant protein technology have facilitated the production of biologically active A2M, enabling detailed studies on its structure-function relationships and therapeutic applications. Researchers are exploring A2M's ability to enhance wound healing, reduce scarring, and promote tissue repair, positioning it as a promising biomolecule in regenerative medicine. Overall, the multifaceted role of A2M in health and disease continues to drive intense investigation, paving the way for novel therapeutic strategies that harness its protective properties against a variety of diseases.